The Directory of Open Access Journals
DOAJ Logotype
Open
Global
Trusted
Main actions
Support
Institutions and libraries
Publishers
Institutional and library supporters
Apply
Application form
Guide to applying
The DOAJ Seal
Transparency & best practice
Publisher information
Licensing & copyright
Search
Menu
Secondary actions
Search
Journals
Articles
Documentation
API
OAI-PMH
Widgets
Public data dump
OpenURL
XML
Metadata help
Preservation
About
About DOAJ
DOAJ at 20
DOAJ team
Ambassadors
Advisory Board & Council
Editorial Policy Advisory Group
Volunteers
News
Support
Institutions and libraries
Publishers
Institutional and library supporters
Apply
Application form
Guide to applying
The DOAJ Seal
Transparency & best practice
Publisher information
Licensing & copyright
Login
Login
Quick search
Close
×
Journals
Articles
Search by keywords:
In the field:
In all fields
Title
ISSN
Subject
Publisher
Country of publisher
Search
Dermatology and Therapy
(Sep 2023)
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Timothy Fitzgerald,
Maryia Zhdanava,
Dominic Pilon,
Aditi Shah,
Patrick Lefebvre,
Steven R. Feldman
Affiliations
Timothy Fitzgerald
Janssen Scientific Affairs, LLC
Maryia Zhdanava
Groupe d’analyse
Dominic Pilon
Groupe d’analyse
Aditi Shah
Groupe d’analyse
Patrick Lefebvre
Groupe d’analyse
Steven R. Feldman
Wake Forest University School of Medicine
DOI
https://doi.org/10.1007/s13555-023-01017-8
Journal volume & issue
Vol. 13, no. 11
pp. 2917 – 2923
Abstract
Read online
No abstracts available.
Keywords
Biologics
Guselkumab
Persistence
Psoriasis
Remission
Treatment discontinuation
WeChat QR code
Close